Anti-cyclic citrullinated peptide antibodies in psoriasis patients without arthritis

Arthritis and Rheumatism

Volumn 54, Issue 5, 2006, Pages 1701-1702

  Böckelmann, Raik ^a   Gollnick, Harald ^a   Bonnekoh, Brnd ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; CYTOKERATIN 17; FILAGGRIN; RHEUMATOID FACTOR;

ADOLESCENT; ADULT; AGED; ANTIBODY TITER; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; PRIORITY JOURNAL; PROGNOSIS; PSORIASIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SCHOOL CHILD; SERUM; T LYMPHOCYTE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; CHILD; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; PSORIASIS;

EID: 33646494178     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21804     Document Type: Article

References (11)

1. Bockelmann R, Horn T, Gollnick H, Bonnekoh B. Interferon-gamma;-dependent in vitro model for the putative keratin 17 autoimmune loop in psoriasis: exploration of pharmaco- and gene-therapeutic effects. Skin Pharmacol Physiol 2005;18:42-54.
2. Bos JD, de Rie MA, Teunissen MBM, Piskin G. Psoriasis: dysregulation of innate immunity. Br J Dermatol 2005;152:1098-107.
3. Winterfield LS, Menter A, Gordon K, Gottlieb A. Psoriasis treatment: current and emerging directed therapies. Ann Rheum Dis 2005;64 (Suppl II):87-90.
4. Sebbag M, Chapuy-Regaud S, Auger I, Petit-Texeira E, Clavel C, Nogueira L, et al. Clinical and pathophysiological significance of the autoimmune response to citrullinated proteins in rheumatoid arthritis. Joint Bone Spine 2004;71:493-502.
5. Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004;50:380-6.
6. Lindqvist E, Eberhardt K, Bendtzen K, Heinegard D, Saxne T. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 2005;64:196-201.
7. Vander Cruyssen B, Hoffman IEA, Zmierczak H, van den Berghe M, Kruithof E, De Rycke L, et al. Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis 2005;64:1145-9.
8. Bogliolo L, Alpini C, Caporali R, Scire CA, Moratti R, Montecucco C. Antibodies to cyclic citrullinated peptides in psoriatic patients. J Rheumatol 2005;32:511-5.
9. Fredriksson T, Pettersson U. Severe psoriasis: oral therapy with a new retinoid. Dermatologica 1978;157:238-44.
10. Matsushita Y, Shimada Y, Kawara S, Takehara K, Sato S. Autoantibodies directed against the protease inhibitor calpastatin in psoriasis. Clin Exp Immunol 2005;139:355-62.
11. Palosuo T, Tilvis R, Strandberg T, Aho K. Filaggrin related antibodies among the aged. Ann Rheum Dis 2003;62:261-3.